Guggenheim Capital’s Charles River Laboratories CRL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$976K Sell
4,303
-858
-17% -$153K 0.01% 1034
2026
Q1
$890K Sell
5,161
-77
-1% -$14.3K 0.01% 1028
2025
Q4
$1.04M Sell
5,238
-815
-13% -$148K 0.01% 929
2025
Q3
$947K Sell
6,053
-231
-4% -$36.7K 0.01% 942
2025
Q2
$953K Sell
6,284
-144
-2% -$19.2K 0.01% 900
2025
Q1
$968K Sell
6,428
-1,825
-22% -$306K 0.01% 888
2024
Q4
$1.52M Buy
8,253
+725
+10% +$140K 0.01% 745
2024
Q3
$1.48M Sell
7,528
-174
-2% -$36.2K 0.01% 942
2024
Q2
$1.59M Sell
7,702
-1,086
-12% -$246K 0.01% 897
2024
Q1
$2.38M Buy
8,788
+125
+1% +$29.9K 0.02% 831
2023
Q4
$2.05M Sell
8,663
-712
-8% -$140K 0.02% 841
2023
Q3
$1.84M Sell
9,375
-177
-2% -$36.3K 0.02% 838
2023
Q2
$2.01M Sell
9,552
-786
-8% -$156K 0.02% 854
2023
Q1
$2.09M Buy
10,338
+1,394
+16% +$316K 0.02% 828
2022
Q4
$1.95M Sell
8,944
-4,211
-32% -$920K 0.02% 867
2022
Q3
$2.59M Sell
13,155
-256
-2% -$55.3K 0.02% 745
2022
Q2
$2.87M Sell
13,411
-1,504
-10% -$368K 0.02% 756
2022
Q1
$4.24M Sell
14,915
-3,807
-20% -$1.17M 0.03% 714
2021
Q4
$7.05M Sell
18,722
-3,030
-14% -$1.18M 0.04% 548
2021
Q3
$8.98M Buy
21,752
+1,619
+8% +$672K 0.05% 425
2021
Q2
$7.45M Buy
20,133
+7,880
+64% +$2.63M 0.04% 506
2021
Q1
$3.55M Buy
12,253
+320
+3% +$89K 0.02% 770
2020
Q4
$2.98M Buy
11,933
+5,050
+73% +$1.2M 0.02% 793
2020
Q3
$1.56M Buy
6,883
+273
+4% +$56.7K 0.01% 999
2020
Q2
$1.15M Buy
6,610
+278
+4% +$44.4K 0.01% 1124
2020
Q1
$799K Sell
6,332
-679
-10% -$102K 0.01% 1188
2019
Q4
$1.07M Buy
7,011
+986
+16% +$137K 0.01% 1299
2019
Q3
$797K Buy
6,025
+353
+6% +$47.3K 0.01% 1419
2019
Q2
$805K Sell
5,672
-249
-4% -$33.8K 0.01% 1447
2019
Q1
$860K Buy
5,921
+1,499
+34% +$197K 0.01% 1455
2018
Q4
$500K Sell
4,422
-59,483
-93% -$7.45M ﹤0.01% 1677
2018
Q3
$8.6M Sell
63,905
-12,837
-17% -$1.58M 0.06% 421
2018
Q2
$8.61M Sell
76,742
-62,969
-45% -$6.81M 0.06% 392
2018
Q1
$14.9M Buy
139,711
+20,697
+17% +$2.23M 0.04% 570
2017
Q4
$13M Buy
119,014
+65,313
+122% +$7.11M 0.03% 609
2017
Q3
$5.8M Buy
53,701
+3,263
+6% +$335K 0.01% 973
2017
Q2
$5.1M Sell
50,438
-4,646
-8% -$428K 0.01% 1006
2017
Q1
$4.96M Sell
55,084
-21,586
-28% -$1.83M 0.01% 1027
2016
Q4
$5.84M Sell
76,670
-57,177
-43% -$4.34M 0.02% 908
2016
Q3
$11.2M Sell
133,847
-3,464
-3% -$290K 0.03% 625
2016
Q2
$11.3M Sell
137,311
-15,562
-10% -$1.28M 0.04% 631
2016
Q1
$11.6M Sell
152,873
-30,785
-17% -$2.28M 0.04% 659
2015
Q4
$14.8M Sell
183,658
-54,771
-23% -$3.95M 0.04% 628
2015
Q3
$15.1M Buy
238,429
+2,370
+1% +$170K 0.05% 615
2015
Q2
$16.6M Buy
236,059
+22,496
+11% +$1.66M 0.04% 659
2015
Q1
$16.9M Buy
213,563
+7,016
+3% +$518K 0.04% 668
2014
Q4
$13.1M Sell
206,547
-22,284
-10% -$1.4M 0.03% 736
2014
Q3
$13.7M Sell
228,831
-6,171
-3% -$353K 0.03% 778
2014
Q2
$12.6M Sell
235,002
-27,247
-10% -$1.5M 0.03% 787
2014
Q1
$15.8M Buy
262,249
+30,769
+13% +$1.79M 0.05% 719
2013
Q4
$12.3M Buy
231,480
+5,763
+3% +$289K 0.04% 765
2013
Q3
$10.4M Buy
225,717
+26,989
+14% +$1.24M 0.04% 826
2013
Q2
$8.15M Buy
+198,728
New +$8.51M 0.03% 857

Other funds holding CRL

Guggenheim Capital's CRL Position: Q2 2026 in Review

Guggenheim Capital reduced its Charles River Laboratories (CRL) stake by 17% in Q2 2026, selling an estimated $153K and leaving 4,303 shares worth $976K. The position accounts for 0.01% of the portfolio, ranked #1034.

Guggenheim Capital first reported a position in CRL in Q2 2013 and has held it in 53 quarters since. The position peaked at $16.9M in Q1 2015. 568 funds tracked by Wall St. Rank hold CRL as of Q2 2026.

  • Guggenheim Capital held 4,303 shares of Charles River Laboratories worth $976K as of Q2 2026.
  • Guggenheim Capital sold 858 Charles River Laboratories shares in Q2 2026, an estimated $153K.
  • Charles River Laboratories made up 0.01% of Guggenheim Capital's portfolio in Q2 2026, its #1034 holding.
  • Guggenheim Capital first reported a position in Charles River Laboratories in Q2 2013 and has held it in 53 quarters since.
  • Guggenheim Capital's Charles River Laboratories position peaked at $16.9M in Q1 2015.
  • 568 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.

Based on Guggenheim Capital's 13F filing for Q2 2026, filed 12 Aug 2026.